Lexicon Pharma (LXRX) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 First Quarter Financial Results
May 3, 2016 7:00 AM EDTTHE WOODLANDS, Texas, May 3, 2016 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2016 and provided an overview of key milestones for the company's lead drug candidates.
"We closed out the quarter with the filing of the NDA for telotristat etiprate, an important milestone for the company," said Lexicon President and Chief Executive Officer, Lonnel Coats. "We look forward to working closely with the FDA during the review process of this... More
